Arturo Araya, MBA

CHIEF COMMERCIAL OFFICER
Arturo Araya joined Cell-Gene company in February 2017. He has nearly two decades of international pharmaceutical experience in the commercialization, marketing, and general management of cellular therapies. At Novartis’s Cell and Gene Therapies Unit, he was Vice President and Head of Global Commercial, where he led a cross-functional team to commercialize a portfolio of cellular and gene therapies. As Global Brand Leader for CTL019, a chimeric antigen receptor (CAR)-T cell therapy, he was responsible for developing early launch plans, including worldwide and multiple indication forecasts and resource modeling. He led the Oncology Unit for Novartis in seven countries. Prior to Novartis, Mr. Araya was with Bristol-Myers Squibb as Associate Director of Marketing Intelligence, Business Development & Licensing.
Mr. Araya earned an MBA from the University of Michigan. He also holds an MA in Political Science and a BS in Civil Engineering from the University of Connecticut.
Scroll to Top

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.